July 24, 2006
LONDON, Ontario—A study on the effects of Sytrinol®, a proprietary ingredient developed by KGK Synergize, on glycemic control was presented at the Canadian Federation of Biological Sciences’ 48th Annual Meeting. In an initial double blind, placebocontrolled clinical trial, supported by KGK, three months’ administration of Sytrinol to subjects with moderate hypercholesterolemia significantly reduced total and low-density lipoprotein (LDL) cholesterol. In a second stage, 10 of the initial subjects (seven women, three men) who also had metabolic syndrome participated in two, 2-hour standard 25 g oral glucose tolerance tests (OGTT), one before intervention and one after. Administration of Sytrinol was associated with a more pronounced tendency to improved OGTT insulin responses. The positive glycemic control results were significantly correlated with body mass index (BMI).
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023